Skip to content

Arno Therapeutics, Inc: 10-Q filed 2016-08-22

What Arno Therapeutics, Inc reported in its quarterly report filed 2016-08-22 (fiscal Q2 2016): 24 published measures, 66 facts as tagged in accession 0001144204-16-120593.

This filing

Form
10-Q (quarterly report)
Filed
2016-08-22
Fiscal period
fiscal Q2 2016
Accession
0001144204-16-120593 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Arno Therapeutics, Inc filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2016-06-301,098,803USD
At 2015-12-31361,240USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2016-06-306,317,316USD
At 2015-12-318,985,334USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2016-06-30-5,218,513USD
At 2015-12-31-8,624,094USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2016-06-30937,355USD
At 2015-12-3166,988USD
At 2015-06-302,368,114USD
At 2014-12-317,948,436USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-2,142,488USD91
2016-01-01 to 2016-06-30-5,851,435USD182
2015-04-01 to 2015-06-30-3,444,875USD91
2015-01-01 to 2015-06-30-6,833,666USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2016-06-30-99,146,388USD
At 2015-12-31-93,294,953USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2016-06-3019,542USD
At 2015-12-3123,103USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2016-01-01 to 2016-06-301,921,365USD182
2015-01-01 to 2015-06-301,922,959USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2016-04-01 to 2016-06-30-3,310,534USD91
2016-01-01 to 2016-06-30-6,135,820USD182
2015-04-01 to 2015-06-30-3,979,000USD91
2015-01-01 to 2015-06-30-7,841,484USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2016-06-301,068,806USD
At 2015-12-31327,682USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2016-04-01 to 2016-06-30250USD91
2016-01-01 to 2016-06-3014,768USD182
2015-04-01 to 2015-06-30380USD91
2015-01-01 to 2015-06-30790USD181

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2016-06-301,784,486USD
At 2015-12-314,230,577USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2016-06-30709,401USD
At 2015-12-311,010,215USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2016-04-01 to 2016-06-303,310,534USD91
2016-01-01 to 2016-06-306,135,820USD182
2015-04-01 to 2015-06-303,979,000USD91
2015-01-01 to 2015-06-307,841,484USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2016-04-01 to 2016-06-302,056,151USD91
2016-01-01 to 2016-06-303,600,489USD182
2015-04-01 to 2015-06-302,647,781USD91
2015-01-01 to 2015-06-305,122,650USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2016-06-3041,562,613shares
At 2015-12-3120,408,616shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2016-06-3093,920,291USD
At 2015-12-3184,665,390USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2016-06-300USD
At 2015-12-312,089,909USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2016-06-30131,451USD
At 2015-12-31260,694USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,254,383USD91
2016-01-01 to 2016-06-302,535,331USD182
2015-04-01 to 2015-06-301,331,219USD91
2015-01-01 to 2015-06-302,718,834USD181

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,167,349USD91
2016-01-01 to 2016-06-30296,167USD182
2015-04-01 to 2015-06-30531,932USD91
2015-01-01 to 2015-06-301,001,513USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2016-04-01 to 2016-06-301,168,046USD91
2016-01-01 to 2016-06-30284,385USD182
2015-04-01 to 2015-06-30534,125USD91
2015-01-01 to 2015-06-301,007,818USD181

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2016-01-01 to 2016-06-305,206,999USD182
2015-01-01 to 2015-06-300USD181

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2016-01-01 to 2016-06-30-300,814USD182
2015-01-01 to 2015-06-30346,565USD181

Inspect the source

Entity
Arno Therapeutics, Inc / CIK 0001195116
Captured
SEC response SHA-256
daf59b1b66be981617a28a70398e42d86562bef04d5c645d4ccff16477481049

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001195116.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))